VERTEX PHARMACEUTICALS INC / MA (VRTX)

Pharmaceutical Preparations

Latest Price

$477.10

TTM P/E

28.31

Normalized P/E

45.12

Div Yield

Book Value

76.20

P/B Ratio

6.26

Valuation metrics

EPS: $15.32

Book value / share: $73.49

Formula: √(22.5 × EPS × BVPS)

Graham Number

$159.16

67% downside

Norm. op. income: $2.9B (median of 7yr)

Tax rate: 15%

Discount rate: 10%

Growth assumption: zero (EPV is a no-growth value)

Earnings Power Value

$121.33

75% downside

Base FCF: $3.3B (median of recent 5yr)

Growth: 5%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$245.35

49% downside

EPS: $15.32

Target P/E: 45×

Formula: EPS × P/E

P/E Fair Value

$689.40

+44% upside

87.5% held by institutions

Institution	Shares	Value	Ownership %	Change	Filing Date
Capital World Investors	25.37M	$11.33B	9.98%	-142.1K	2026-03-31
BlackRock, Inc.	23.97M	$10.70B	9.43%	+217.5K	2026-03-31
Capital Research Global Investors	21.13M	$9.43B	8.31%	+3.81M	2026-03-31
VANGUARD CAPITAL MANAGEMENT LLC	16.51M	$7.37B	6.50%	--	2026-03-31
STATE STREET CORP	11.73M	$5.24B	4.62%	+40.6K	2026-03-31
GEODE CAPITAL MANAGEMENT, LLC	6.14M	$2.73B	2.42%	+157.7K	2026-03-31
VANGUARD PORTFOLIO MANAGEMENT LLC	5.15M	$2.30B	2.02%	--	2026-03-31
Capital International Investors	5.13M	$2.29B	2.02%	+392.5K	2026-03-31
LOOMIS SAYLES & CO L P	4.00M	$1.79B	1.58%	-29.7K	2026-03-31
ALLIANCEBERNSTEIN L.P.	3.91M	$1.77B	1.54%	-585.7K	2026-03-31